Private Companies 27

UK

June 19, 2018: Atlas Genetics Ltd. issued new U.S. patent [9,999,883]

NEWS BITES - PRIVATE COMPANIES

Atlas Genetics Ltd. has been issued a new U.S. patent titled "System and method for processing fluid in a fluidic cartridge" by the US Patent and Trademark Office.

ABSTRACT

A system and method for processing fluid in a fluidic cartridge is provided. The system comprises a fluid pathway for passing a liquid sample therethrough from an upstream end to a downstream end, a sample processing chamber within the fluid pathway having an inlet valve upstream of the sample processing chamber, a downstream sample processing region within the fluid pathway downstream of the outlet valve and a bypass channel coupled to the fluid pathway at a junction between the outlet valve and the downstream sample processing region, the valve system configured such that surplus liquid downstream of the outlet valve may be evacuated through the bypass channel when the outlet valve is closed, thereby leaving a metered volume of liquid sample between the inlet valve and the downstream sample processing region.

Appl. No.14/906,970
PCT FiledJuly 28, 2014
PCT No.PCT/GB2014/052307

INDEX

SECTION 1 ATLAS GENETICS LTD. FINANCIALS

SECTION 2 ATLAS GENETICS LTD. PROFILE

SECTION 3 PRESS RELEASES: 2018

SECTION 4 PRESS RELEASES: 2017

SECTION 5 OTHER NEWS: 2017

SECTION 6 OTHER NEWS: 2014

SECTION 7 ATLAS GENETICS LTD. PATENTS

SECTION 8 ATLAS GENETICS LTD. TOP MANAGEMENT

SECTION 1 ATLAS GENETICS LTD. FINANCIALS

FY2016 Annual Report: Atlas Genetics Ltd. reports Loss of GBP9.3m ($US11.4m)

Major changes compared with previous year:

Favourable Changes:

Total non-current assets to Total Assets up from 24% to 41%

Fixed Assets to Total Assets up from 18% to 28%

Unfavourable Changes:

Loss of GBP9.3m ($US11.4m)

Operating Cash Flow is negative

Current ratio down 72% from 9.2 to 2.6

Working capital to total assets down from 68.0% to 36.6%

Total current assets to Total Assets down from 76% to 59%

Cash to Total Assets down from 65% to 38%

Note:

Intangibles to Total Assets up from 6% to 14%

Annual

Company Name : Atlas Genetics Ltd.
December 312016201520162015Change
DescriptionGBP ('000)GBP ('000)$US ('000)$US ('000)(%)
Sales Revenue374647461959Down 42
EBITDA(7,741)(6,672)(9,554)(9,895)Deterioration 16
Depreciation478316590469Up 51
EBIT(8,219)(6,989)(10,144)(10,364)Deterioration 18
Interest2,3942,2792,9553,380Up 5
Pre-Tax Profit/(Loss)(10,613)(9,268)(13,099)(13,744)Deterioration 15
Profit/(Loss) after Tax(9,268)(7,839)(11,439)(11,626)Deterioration 18
Working Capital2,7959,1723,45013,602Down 70
Current Assets4,50610,2875,56115,255Down 56
Current Liabilities1,7101,1152,1111,653Up 53
Shareholders' Funds(37,318)(28,479)(46,061)(42,235)Deterioration 31
Total Liabilities44,96241,96555,49562,234Up 7
Total Assets7,64413,4869,43520,000Down 43
Non-Current Debt43,25240,85053,38460,581Up 6
Total Debt43,25240,85053,38460,581Up 6
Cash and cash equivalents2,8688,7103,54012,916Down 67
Operating Cash Flow(5,285)(5,471)(6,523)(8,113)Improved 3
Net Tangible Assets(38,356)(29,243)(47,341)(43,368)Deterioration 31
AuditorPRICEWATERHOUSECOOPERS LLP  

Currency Conversion (December 31, 2016): $US1 = GBP0.81

Currency Conversion (December 31, 2015): $US1 = GBP0.67

SECTION 2 ATLAS GENETICS LTD. PROFILE

2.1 ACTIVITIES

Atlas Genetics Ltd. develops solutions for the detection of DNA and RNA. It offers Velox, a point-of-care platform to perform a DNA analysis from a clinical sample, such as blood or urine using a discrete test cartridge inserted into a small instrument. The companys platform is used for the diagnosis of chlamydia/gonorrhoea, MRSA, group B streptococcus, bacterial meningitis, and human norwalk viruses in humans, as well as respiratory infections including strangles in equines. It serves clinicians, nurses, and vets. Atlas Genetics Ltd. was incorporated in 2005 and is based in Bristol, the United Kingdom.

2.2 SUMMARY

Fiscal Year End: 31 Dec 2016

PermID: 4297629847

Website: http://www.atlasgenetics.com

Industry: Healthcare Equipment/Supplies

SECTION 3 PRESS RELEASES: 2018

January 05: Atlas Genetics Ltd.: Life Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of Directors

CAMBRIDGE, Mass. & BATH, United Kingdom, January 5, 2018 - Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors. Lapidus has more than 30 years' experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including his founding of EXACT Sciences Corp. (NASDAQ:EXAS) and, prior to that, Cytyc Corp., which was sold to Hologic Corporation in 2007.

"We are honored to have Stan, a true luminary in biotechnology, join Atlas Genetics as its newest board member," said Jeff Luber, President and CEO of Atlas. "He comes to Atlas at a pivotal time as we transition from clinical validation of our proprietary platform in POC testing to becoming a commercially disruptive force globally. As one of the most successful leaders, innovators and entrepreneurs in the diagnostics industry, Stan has provided strategic insights to emerging healthcare companies through similar commercial arcs. His counsel will be invaluable as Atlas capitalizes on a quickly changing healthcare landscape where rapid testing and consumer convenience become increasingly paramount. We view his association with Atlas as another indication of the opportunity here and the great things to come."

Lapidus founded EXACT Sciences and served as its CEO and Chairman until 2006. Since commercial introduction of the company's Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry. Prior to EXACT Sciences, Lapidus was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion.

SECTION 4 PRESS RELEASES: 2017

November 01: Atlas Genetics Ltd.: Atlas Genetics appoints Life Sciences Veteran, Jeffrey Luber, as Chief Executive Officer; founding CEO Dr John Clarkson steps up to Executive Chairman

Expanded Board and Blue Chip Investors Position Company for Global Reach

Bath, UK, 3 October, 2017. Atlas Genetics Ltd., the ultra-rapid, point-of-care (POC) testing company for women's and family health, today announced that Jeffrey R. Luber has been appointed Chief Executive Officer effective 1 October 2017. Dr. John Clarkson, current founding CEO, will become Executive Chairman and current chairman, Neil Butler, will remain with the Company as a non-executive director of the Board.

Mr. Luber joins the Board of Atlas Genetics with broad experience in the life sciences industry, including having held multiple leadership roles in both public and private companies. Most recently, he led the return to growth and sale of Good Start Genetics to Invitae Corp (NYSE: NVTA). In this role, Jeff led the company in new directions, restoring growth to its core business, expanding its reach into consumer markets, and entering into transformative strategic partnerships with Roche Diagnostics and Amazon. Prior to this, Jeff was CEO of EXACT Sciences (NASDAQ: EXAS) where he executed its successful turnaround and strategic transaction with Genzyme Corp.

Dr. John Clarkson, founding CEO of Atlas Genetics, said: "We are delighted to welcome Jeff to Atlas Genetics. Jeff's proven track record and extensive experience in the commercialisation of in vitro diagnostics will be invaluable as we enter the next, exciting phase of growth aimed at improving the diagnosis and treatment of conditions affecting women and families."

Source: Company Website

SECTION 5 OTHER NEWS: 2017

January 23: Atlas Genetics Ltd.: Atlas Genetics raises $35m in Series D fundraising

Atlas Genetics Ltd., the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces completion of its Series D financing, raising $35 million from a syndicate including all Series C Investors and one new investor, Wondfo Biotech. Development of the Atlas Genetics io(Registered) system has been completed with the successful CE marking of the Chlamydia trachomatis (CT) test announced in February 2016. This new Series D equity issue will finance the clinical trials and commercial launch of a second test, for detection of both Chlamydia and Gonorrhoea, planned for regulatory approvals in the US around the end of 2017, as well as further development of additional diagnostics menu. The financing also provides funding to expand cartridge manufacturing capacity at Bespak, Atlas Genetics' cartridge manufacturing partner. The io(Registered) system is a highly novel molecular diagnostic platform for the ultra-rapid diagnosis of a broad range of infectious diseases. The system offers a sample-to-answer time of under 30 minutes making it possible to carry out infectious disease tests in primary care clinics and physicians' offices that are as accurate as those carried out in hospital laboratories.

SECTION 6 OTHER NEWS: 2014

June 19: Atlas Genetics wins "Best for Innovation" in the BVCA Management Team Awards

[Company Release]

Bath, UK, 19th June, 2014. Atlas Genetics Ltd ("Atlas" or the "Company"), the diagnostic company developing ultra-rapid point-of-care (POC) tests for a range of infectious diseases, has won the "Best for Innovation" award in the BVCA Management Team Awards 2014 for the South West region.

The prize was given out by the British Private Equity and Venture Capital Association (BVCA), the industry body and public policy advocate for the private equity and venture capital industry in the UK. The BVCA Management Team Awards are an annual celebration of the best and brightest UK businesses which are supported by private equity and venture capital. The "Best for Innovation" award aims to recognise the achievements of the management teams of eligible companies in driving innovation.

Atlas Genetics has developed the io system, a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases including Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs). The io system will make it possible, for the first time, to carry out a broad range of infectious disease tests in primary care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories.

June 17: Atlas completes development of io(TradeMark) Cartridge and establishes manufacturing capability at Bespak UK

[Company Release]

Bath, UK, 17 June, 2014. Atlas Genetics Ltd ("Atlas" or the "Company"), developer of innovative, ultra-rapid diagnostics to enable a 'test and treat' solution to infectious diseases, today announces that the installation and commissioning of its manufacturing line for the Atlas io(Registered) Cartridge at Bespak has completed. The io Cartridge was developed in collaboration with Bespak for use with the Atlas io Reader, which together form a Point of Care system that can deliver laboratory quality results for molecular assays in under thirty minutes.

The io system is a highly novel molecular diagnostic system for the ultra-rapid diagnosis of a broad range of infectious diseases including Sexually Transmitted Infections (STIs) and Hospital Acquired Infections (HAIs). It is based on a patent-protected electrochemical sensor technology that combines speed, accuracy and low manufacturing costs. The fully integrated Cartridge contains all reagents on board and is designed to receive an unprocessed clinical specimen. The Cartridge is then inserted into the Reader which then completes the three-stage process of sample preparation, DNA amplification and electrochemical detection, to analyse the patient's sample for the target infection.

In addition to deployment in hospital settings, the io system will make it possible, for the first time, to carry out a broad range of infectious disease tests in primary care clinics and GP surgeries that are as accurate as those carried out in hospital laboratories.

SECTION 7 ATLAS GENETICS LTD. PATENTS

7.1 Number of Patents Issued to Atlas Genetics Ltd. (Past 12 Months)

There were a total of 5 patents issued to Atlas Genetics Ltd. in the past 12 months. The highest number (2) were issued in November, 2017.

MonthNo. of Patents Issued
June1
May1
March1
November2
Total (Past 12 Months)5

7.2 Patents issued by the US PTO and the EPO on same inventions

In the past 24 months the following patent was issued by the USPTO and the European Patent Office (EPO) to Atlas Genetics Ltd..

TitleUS PTOEPO
System And Method For Processing Fluid In A Fluidic Cartridge9,999,883; 19 Jun, 2018EP3144067 (A1); 22 Mar, 2017

7.3 Previous 5 ATLAS GENETICS LTD. Patent titles:

Issue DateIssuing OfficePatent TitlePatent Number
Jun 12, 2018US PTOValve which depressurises, and a valve system9,993,818
May 29, 2018US PTOMicrobial assay9,982,312
Mar 6, 2018US PTOCartridge, cartridge reader and method for preventing reuse of the cartridge9,908,114
Nov 21, 2017US PTOLabelling compounds and their use in assays9,822,398
Nov 14, 2017US PTOFluidic cartridge for nucleic acid amplification and detection9,816,135

7.4 Previous 5 ATLAS GENETICS LTD. Patent abstracts:

June 12, 2018 Atlas Genetics Ltd. issued new U.S. patent [9,993,818]

ABSTRACT

been issued a new U.S. patent titled "Valve which depressurises, and a valve system" by the US Patent and Trademark Office. The patent number is 9,993,818 and was issued on June 12, 2018.



ABSTRACT



A valve for a fluidic cartridge is provided. The valve comprises a valve cavity having first and second openings connected to first and second passageways, respectively; and a flexible membrane within the valve cavity, the flexible membrane having a first portion actuatable to seal against the first opening and a second portion actuatable to seal against the second opening; wherein the valve cavity is configured such that the first flexible membrane portion may be actuated independently of the second flexible membrane portion to enable the first opening to be sealed independently of the second.

May 29, 2018 Atlas Genetics Ltd. issued new U.S. patent [9,982,312]

ABSTRACT

been issued a new U.S. patent titled "Microbial assay" by the US Patent and Trademark Office. The patent number is 9,982,312 and was issued on May 29, 2018.



ABSTRACT



A method of detecting genetic material deriving from Chlamydia trachomatis comprising detection of a specified nucleic acid sequence, optionally using specific primers and probes and optionally in combination with the detection of genetic material deriving from Pectobacterium atrosepticum as an internal control; and related products and kits.

March 6, 2018 Atlas Genetics Ltd. issued new U.S. patent [9,908,114]

ABSTRACT

A disposable fluidic cartridge has a recess therein. A mechanically-actuated mechanism is disposed within the recess for effecting an operation of the fluidic cartridge. The cartridge further comprises a machine-readable identification code on a breakable label covering at least a portion of the recess such that the portion of the breakable label covering the recess may be broken upon insertion of a mechanical actuator into the recess to actuate the mechanically-actuated mechanism. This renders the identification code unreadable and prevents reuse of the cartridge.

November 21, 2017 Atlas Genetics Ltd. issued new U.S. patent [9,822,398]

ABSTRACT

The invention provides monoferrocenyl compounds of general formula (I). The invention also provides substrates labelled with the compounds, functionalised derivatives of the compounds and methods of using the compounds, functionalised derivatives and labelled substrates in electrochemical assays.

November 14, 2017 Atlas Genetics Ltd. issued new U.S. patent [9,816,135]

ABSTRACT

A cartridge for assay of a target nucleic acid sequence in a liquid sample. The cartridge comprises: a fluidic portion through which the sample flows and in which nucleic acid amplification and detection takes place; a pneumatic portion which controls flow through the fluidic portion; and at least two electrodes which provide a potential difference for the detection of an amplified nucleic acid of interest.

SECTION 8 ATLAS GENETICS LTD. TOP MANAGEMENT

John Clarkson, CEO

John Clarkson has been in healthcare and diagnostics businesses for the past 15 years and has a background in molecular biology. He co-founded Molecular Sensing plc where he was Commercial Director and then Technical Director. Following the successful development of their DNA analysis system, he joined the US-based diagnostics company Osmetech plc when they acquired Molecular Sensing in 2004. John led the formation of Atlas in 2005 and was founding Chief Executive.

PermID: 4297629847

Created by www.buysellsignals.com for News Bites Finance